Abstract:BACKGROUND:Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder involving gut-brain interactions with limited effective treatment options. Vitamin D deficiency is commonly observed in patients with IBS, but whether vitamin D supplementation ameliorates IBS is controversial in randomized controlled trials. The present systematic review and meta-analysis explored the efficacy of vitamin D supplementation in patients with IBS. METHODS:We performed a systematic search of potentially relevant publications from PubMed, EMBASE, the Cochrane Central Register of Controlled Studies and the Web of Science up until January 2022. We assessed the weighted mean difference (WMD) and 95% confidence interval (95% CI) of the IBS severity scoring system (IBS-SSS), IBS quality of life (IBS-QoL) and IBS total score (IBS-TS) before and after vitamin D supplementation intervention. RESULTS:We included four randomized, placebo-controlled trials involving 335 participants. The differences in IBS-SSS score between participants in the intervention group and the placebo group increased after intervention (WMD: -55.55, 95% CI: -70.22 to -40.87, I2 = 53.7%, after intervention; WMD: -3.17, 95% CI: -18.15 to 11.81, I2 = 0.0%, before intervention). Participants receiving vitamin D supplementation showed greater improvement in IBS-SSS after intervention than participants receiving placebo treatment (WMD: -84.21, 95% CI: -111.38 to -57.05, I2 = 73.2%; WMD: -28.29, 95% CI: -49.95 to -6.62, I2 = 46.6%, respectively). Vitamin D supplementation was also superior to placebo in IBS-QoL improvement (WMD: 14.98, 95% CI: 12.06 to 17.90, I2 = 0.0%; WMD: 6.55, 95% CI: -2.23 to 15.33, I2 = 82.7%, respectively). Sensitivity analyses revealed an unstable pooled effect on IBS-TS in participants receiving vitamin D supplementation. Therefore, we did not evaluate the efficacy of vitamin D intervention in IBS-TS. CONCLUSIONS:This systematic review and meta-analysis suggested that vitamin D supplementation was superior to placebo for IBS treatment.

Vitamin D, the gut microbiome and inflammatory bowel disease

Vitamin D Modulates Intestinal Microbiota in Inflammatory Bowel Diseases

Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review

Vitamin D and the Pathogenesis of Inflammatory Bowel Disease

[Association between vitamin D and inflammatory bowel diseases]

The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management

Inflammatory bowel diseases: interrelationships between dietary vitamin D, exposure to UV radiation and the fecal microbiome

Interplay of Immunity and Vitamin D: Interactions and Implications with Current IBD Therapy

Vitamin D Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis

The Efficacy of Vitamin D Supplementation for Irritable Bowel Syndrome: a Systematic Review with Meta-Analysis

Vitamin D Axis in Inflammatory Bowel Diseases: Role, Current Uses and Future Perspectives

Possible Molecular Mechanisms by Which Vitamin D Prevents Inflammatory Bowel Disease and Colitis-associated Colorectal Cancer.

Mucosal vitamin D signaling in inflammatory bowel disease

Contemporary Perspectives on the Role of Vitamin D in Enhancing Gut Health and Its Implications for Preventing and Managing Intestinal Diseases

Exploring the Role of Vitamin D and the Vitamin D Receptor in the Composition of the Gut Microbiota

The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status

Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier

Effects of oral vitamin D supplementation on inflammatory bowel disease: a systematic review and meta-analysis

Vitamin–Microbiota Crosstalk in Intestinal Inflammation and Carcinogenesis

[Role of vitamin D in pediatric irritable bowel syndrome].

Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis